Skip to main
WGS

WGS Stock Forecast & Price Target

WGS Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GeneDx Holdings is a leading player in the genomics space, with a strong focus on rare and ultra-rare pediatric disorders. The company's exome and genome sequencing technology has the potential to revolutionize healthcare by allowing for proactive genetic testing and earlier diagnosis for patients. While the company has faced some challenges in its revenue guidance and execution, its ongoing investment in sales force and continued focus on exome and genome testing should drive growth and improved financial performance in the long term.

Bears say

GeneDx Holdings is a rapidly growing market leader in rare-disease testing lab services, but its Q1 results missed expectations, with a weaker outlook for full-year revenue and volume growth. The company is facing headwinds from mix and softness in non-core businesses, and there are risks related to the adoption of whole exome and whole genome tests and the slow growth of the rare disease market. Despite its potential and strong industry positioning, GeneDx will likely face challenges in the short term and its stock has a negative outlook for now.

WGS has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GeneDx Holdings Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GeneDx Holdings Corp (WGS) Forecast

Analysts have given WGS a Strong Buy based on their latest research and market trends.

According to 5 analysts, WGS has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GeneDx Holdings Corp (WGS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.